BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22279422)

  • 1. Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
    Sreenath TL; Dobi A; Petrovics G; Srivastava S
    J Carcinog; 2011; 10():37. PubMed ID: 22279422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.
    Rawal S; Young D; Williams M; Colombo M; Krishnappa R; Petrovics G; McLeod DG; Srivastava S; Sesterhenn IA
    J Cancer; 2013; 4(6):468-72. PubMed ID: 23901346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors.
    Dubovenko A; Serebryiskaya T; Nikolsky Y; Nikolskaya T; Perlina A; JeBailey L; Bureeva S; Katta S; Srivastava S; Dobi A; Khasanova T
    J Cancer; 2015; 6(6):490-501. PubMed ID: 26000039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.
    Mwamukonda K; Chen Y; Ravindranath L; Furusato B; Hu Y; Sterbis J; Osborn D; Rosner I; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):47-51. PubMed ID: 19597533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
    Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
    Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
    Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.
    Furusato B; Tan SH; Young D; Dobi A; Sun C; Mohamed AA; Thangapazham R; Chen Y; McMaster G; Sreenath T; Petrovics G; McLeod DG; Srivastava S; Sesterhenn IA
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):228-37. PubMed ID: 20585344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression.
    St John J; Powell K; Conley-Lacomb MK; Chinni SR
    J Cancer Sci Ther; 2012 Apr; 4(4):94-101. PubMed ID: 23264855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
    Guo XQ; Gui YT; Cai ZM
    Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
    Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 14. Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.
    Lorenzin F; Demichelis F
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
    Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
    Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
    Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
    Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.
    Raymundo EM; Diwa MH; Lapitan MC; Plaza AB; Sevilleja JE; Srivastava S; Sesterhenn IA
    Prostate; 2014 Aug; 74(11):1079-85. PubMed ID: 24909781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.